Otros idiomas Mesoblast Limited Nasdaq

Acciones

MESO

US5907174016

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:00 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
7,5 ^USD	+2,88 %		+20,19 %	+240,91 %

26/03	La FDA dice que los datos del ensayo de Mesoblast son suficientes para apoyar la presentación de la BLA	MT
26/03	Actualización del sector: Los valores del sector sanitario avanzan a última hora de la tarde	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024	30/04
ADRs End Higher; Connect Biopharma Climbs 26%	01/04
ADRs End Lower; NuCana Slides 15%	28/03
Reddit Inc. (NYSE: RDDT) Surges, Uncovering Undervalued Opportunities: DYAI, INBS, MESO, VTAK	28/03
ADRs End Lower; Quhuo Drops 53%	26/03
FDA Says Mesoblast Trial Data Sufficient to Support BLA Submission	26/03
Sector Update: Health Care Stocks Advance Late Afternoon	26/03
Top Midday Gainers	26/03
Sector Update: Health Care Stocks Steady Premarket Tuesday	26/03
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	26/03
Top Premarket Gainers	26/03
Mesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L Application	26/03
Mesoblast to Resubmit Application for Potential Pediatric Treatment of Graft Versus Host Disease; Shares Gain Pre-Bell	26/03
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)	26/03
United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease	26/03
Mesoblast Limited(ASX:MSB) added to S&P/ASX Emerging Companies Index	18/03
Mesoblast Raises AU$97 Million From Entitlement Offer, Institutional Placement	14/03
Mesoblast Raises AU$97 Million for Phase Three Registration Trials	14/03
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer	14/03
Sector Update: Health Care Stocks Softer Late Afternoon	11/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Mesoblast Limited Nasdaq

Acciones

MESO

US5907174016

Otros idiomas

Filtros